Evidence map›Paper›PMID 35682572›Full record

ArticleInternational journal of molecular sciences2022

The Multidirectional Effect of Azelastine Hydrochloride on Cervical Cancer Cells.

Ewa Trybus, Teodora Król, Wojciech Trybus

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. International journal of molecular sciences · 2024
    Article
  6. Lysosomes as a Target of Anticancer Therapy.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Chemical Stability Study of HMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ewa TrybusDepartment of Medical Biology, The Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.ORCID 0000-0002-8950-8278
Teodora KrólDepartment of Medical Biology, The Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.
Wojciech TrybusDepartment of Medical Biology, The Jan Kochanowski University, Uniwersytecka 7, 25-406 Kielce, Poland.ORCID 0000-0002-5450-922X
Jan Kochanowski University · PL

Funding

Jan Kochanowski University SUPB.RN.21.248
6 · The paper itself

Abstract

A major cause of cancer cell resistance to chemotherapeutics is the blocking of apoptosis and induction of autophagy in the context of cell adaptation and survival. Therefore, new compounds are being sought, also among drugs that are commonly used in other therapies. Due to the involvement of histamine in the regulation of processes occurring during the development of many types of cancer, antihistamines are now receiving special attention. Our study concerned the identification of new mechanisms of action of azelastine hydrochloride, used in antiallergic treatment. The study was performed on HeLa cells treated with different concentrations of azelastine (15-90 µM). Cell cycle, level of autophagy (LC3 protein activity) and apoptosis (annexin V assay), activity of caspase 3/7, anti-apoptotic protein of Bcl-2 family, ROS concentration, measurement of mitochondrial membrane potential (Δψm), and level of phosphorylated H2A.X in response to DSB were evaluated by cytometric method. Cellular changes were also demonstrated at the level of transmission electron microscopy and optical and fluorescence microscopy. Lysosomal enzyme activities-cathepsin D and L and cell viability (MTT assay) were assessed spectrophotometrically. Results: Azelastine in concentrations of 15-25 µM induced degradation processes, vacuolization, increase in cathepsin D and L activity, and LC3 protein activation. By increasing ROS, it also caused DNA damage and blocked cells in the S phase of the cell cycle. At the concentrations of 45-90 µM, azelastine clearly promoted apoptosis by activation of caspase 3/7 and inactivation of Bcl-2 protein. Fragmentation of cell nucleus was confirmed by DAPI staining. Changes were also found in the endoplasmic reticulum and mitochondria, whose damage was confirmed by staining with rhodamine 123 and in the MTT test. Azelastine decreased the mitotic index and induced mitotic catastrophe. Studies demonstrated the multidirectional effects of azelastine on HeLa cells, including anti-proliferative, cytotoxic, autophagic, and apoptotic properties, which were the predominant mechanism of death. The revealed novel properties of azelastine may be practically used in anti-cancer therapy in the future.

Indexed as

Cathepsin DUterine Cervical NeoplasmsApoptosisAutophagyCaspase 3Cell Line, TumorFemaleHeLa CellsHumansPhthalazinesProto-Oncogene Proteins c-bcl-2Reactive Oxygen SpeciesazelastineCaspase 3Cathepsin DPhthalazinesProto-Oncogene Proteins c-bcl-2Reactive Oxygen Speciesapoptosisautophagyazelastinemitotic catastropheoxidative stress

Identifiers

PMID35682572
PMCPMC9180047
OpenAlexW4281573012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.